What is the official website of Gallus BioPharmaceuticals ?

The official website of Gallus BioPharmaceuticals is http://www.Patheon.com.

What is Gallus BioPharmaceuticals's cybersecurity risk score?

Gallus BioPharmaceuticals has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Gallus BioPharmaceuticals experienced?

According to Rankiteo, Gallus BioPharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Gallus BioPharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Gallus BioPharmaceuticals has been affected by a supply chain cyber incident involving Fisher Healthcare, with the incident ID FISMIC1784032242.

Does Gallus BioPharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Gallus BioPharmaceuticals is not certified under SOC 2 Type 1.

Does Gallus BioPharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Gallus BioPharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Gallus BioPharmaceuticals comply with GDPR ?

According to Rankiteo, Gallus BioPharmaceuticals is not listed as GDPR compliant.

Does Gallus BioPharmaceuticals have PCI DSS certification ?

According to Rankiteo, Gallus BioPharmaceuticals does not currently maintain PCI DSS compliance.

Does Gallus BioPharmaceuticals comply with HIPAA ?

According to Rankiteo, Gallus BioPharmaceuticals is not compliant with HIPAA regulations.

Does Gallus BioPharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Gallus BioPharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Gallus BioPharmaceuticals operate in ?

Gallus BioPharmaceuticals operates primarily in the Biotechnology Research industry.

How many employees does Gallus BioPharmaceuticals have ?

Gallus BioPharmaceuticals employs approximately 64 people worldwide.

Does Gallus BioPharmaceuticals own any subsidiaries ?

Gallus BioPharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Gallus BioPharmaceuticals have ?

Gallus BioPharmaceuticals's official LinkedIn profile has approximately 2,567 followers.

What is the NAICS classification code for Gallus BioPharmaceuticals ?

Gallus BioPharmaceuticals is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Gallus BioPharmaceuticals have a Crunchbase profile ?

Yes, Gallus BioPharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/gallus-biopharmaceuticals.

Does Gallus BioPharmaceuticals have a LinkedIn profile ?

Yes, Gallus BioPharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/gallus-biopharmaceuticals.

How many cybersecurity incidents has Gallus BioPharmaceuticals experienced ?

As of July 30, 2026, Rankiteo reports that Gallus BioPharmaceuticals has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Gallus BioPharmaceuticals have ?

Gallus BioPharmaceuticals has an estimated 4,735 peer or competitor companies worldwide.

What types of cybersecurity incidents has Gallus BioPharmaceuticals faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Gallus BioPharmaceuticals

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

Gallus BioPharmaceuticals Vendor Cyber Rating & Cyber Score

patheon.com

cb in

Add Your Compliance Badge

September 30, 2014 - Gallus BioPharmaceuticals, LLC has been acquired by DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees. Please visit the Patheon LinkedIn page to learn more about our expanded capabilities and to follow Patheon. Visit our website at http://www.Patheon.com

Gallus BioPharmaceuticals A.I CyberSecurity Scoring

Scoring History

Gallus BioPharmaceuticals

Gallus BioPharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Fisher Healthcare

Breach

5/2024

Fisher Healthca...

FISMIC178403224...

Gallus BioPharmaceu...

Breach

7/2017

THE206072925

Loading…

A.I.

Gallus BioPharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Gallus BioPharmaceuticals

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Gallus BioPharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Gallus BioPharmaceuticals in 2026.

Incident Types Gallus BioPharmaceuticals vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Gallus BioPharmaceuticals in 2026.

Incident History - Gallus BioPharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Gallus BioPharmaceuticals Subsidiaries

Gallus BioPharmaceuticals

Biotechnology Research

Website: http://www.Patheon.com

Company Size: 64

PatheonPharmaceutical Manufacturing

Thermo Fisher ScientificBiotechnology Research

PPDResearch Services

Accelerated Enrollment SolutionsPharmaceutical Manufacturing

PPD™ Laboratory ServicesPharmaceutical Manufacturing

EvideraResearch Services

PPD™ Biotech SolutionsPharmaceutical Manufacturing

Thermo ScientificBiotechnology Research

Accelerating MicroscopyBiotechnology

Chromatography & Mass SpectrometryBiotechnology

FEI CompanyNanotechnology Research

Unity Lab ServicesBiotechnology Research

Fisher HealthcareHospitals and Health Care

Advancing MaterialsResearch Services

Thermo Fisher Spectral CytometryBiotechnology Research

Laureate Biopharmaceutical ServicesBiotechnology Research

Laureate PharmaBiotechnology Research

Loading…

Gallus BioPharmaceuticals Similar Companies

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Amgen

amgen.com

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

Loading…

NEWS

Gallus BioPharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-67595

SUMMARY

VaahCMS versions 2.0.0 through 2.3.4 contain a malicious obfuscated JavaScript payload embedded in the Blade template responsible for rendering security OTP emails, allowing remote attackers to execute unauthorized code in any browser that renders the affected email template with JavaScript enabled. The payload establishes a WebSocket connection to a hardcoded command-and-control endpoint, installs a password-field keylogger using MutationObserver to capture dynamically added inputs, scrapes WhatsApp Web DOM content, and accepts remote commands to redirect or overwrite the rendered page.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.2

REFERENCES

CVE-2026-15157

SUMMARY

undici does not validate the type property of a duck-typed blob-like request body before using it as the Content-Type header on the HTTP/1.1 dispatcher. In undici before 6.28.0, from 7.0.0 up to before 7.29.0, and from 8.0.0 up to before 8.9.0, an application that passes a hand-rolled blob-like body (via request, stream, pipeline, or dispatch) whose type is derived from untrusted input allows an attacker to inject CRLF sequences and append arbitrary HTTP headers, potentially smuggling a second request past the upstream. Native Blob objects are safe because their constructor strips CRLF from the type, and fetch is unaffected because it validates headers, but ecosystem libraries that build duck-typed blob shapes from user input can reach the vulnerable path. This is the same defect class as CVE-2022-35948 and CVE-2026-1527, on a header sink that the earlier fixes did not cover. The issue is fixed in undici 6.28.0, 7.29.0, and 8.9.0.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: 4.2)

cvss3

Base Score: 4.2

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

1.6

REFERENCES

CVE-2026-14643

SUMMARY

undici's cache interceptor mishandles optional whitespace placed around the equals sign of a qualified no-cache or private Cache-Control directive. In undici from 7.0.0 up to before 7.29.0 and from 8.0.0 up to before 8.9.0, the parser either drops the directive or stores a field name with literal quote characters, so the cache decision fails to recognize the qualification and the response is stored. In shared-cache mode, this lets a response containing one user's authenticated data be served from cache to a later caller, including an unauthenticated one, when both requests resolve to the same cache key. It affects applications that enable the cache interceptor in shared mode, forward Authorization headers upstream, and receive cacheable responses with qualified directives padded with whitespace around the equals sign. This is the whitespace-around-equals variant that the fix for CVE-2026-9678 did not normalize, and it is fixed in undici 7.29.0 and 8.9.0.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2025-69949

SUMMARY

kishan0725 Hospital Management System 4.0 is vulnerable to SQL Injection in check_availability.php via the parameters emailid and email.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2025-69945

SUMMARY

kishan0725 Hospital Management System 4.0 is vulnerable to SQL Injection in /doctor/edit-patient.php?editid=1.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/um-dsp/TaintRadar/blob/main/sql_injection_cves/hospitalmanagementsystemproject/20250811-hospital-management-system-edit-patient.php-editid-sqli/20250811-hospital-management-system-edit-patient.php-editid-sqli.md

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…